Menu

Top Stories

Published on Thursday, April 11, 2019

Moderated discussion: “Advancing the innovation ecosystem: Working together for patients,” in Washington, DC

Moderated discussion: “Advancing the innovation ecosystem: Working together for patients,” in Washington, DC

On April 3, 2019, Francis Collins, MD, PhD, director of the National Institutes of Health (NIH), Mikael Dolsten, MD, PhD, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer, joined in a discussion led by Susan Dentzer, visiting fellow at the Robert J. Margolis Center for Health Policy, Duke University, in Washington DC.

Photo: Francis Collins, MD, PhD, director of the NIH (left) and author Alejandro Hernandez, editorial manager of the Alpha-1 Foundation (right)

For 60 minutes, Collins, Dolsten, and Dentzer engaged in a conversation with the theme of: “Advancing the innovation ecosystem: working together for patients,” where they emphasized the need for continued collaboration between the private and public sectors, along with the patient community, in order to advance new and emerging technologies and innovative approaches for potentially life-saving treatments and new outcomes in medicine.

“We are currently living in remarkable times with amazing things happening in areas such as cancer immuno-therapy, gene therapy, and gene editing. The things that are happening right now, I had no idea they would even be possible just five or six years ago,” expressed Collins when asked about the current position “the ecosystem,” as they described the collaboration between the private and public sectors with small biotech companies; an ecosystem with symbiotic characteristics where all contributors play an important role in a tremendous team effort, in medical research.

Collins and Dolsten agreed on the importance of advocacy groups and organizations as well as the patient community, in being part of the process for better outcomes and the ability to bring new and potential treatments for various conditions to the clinic, including rare diseases, such as Alpha-1 Antitrypsin Deficiency (Alpha-1). 

“We need you, the patient community, you are the reason we have gotten this far,” said Collins.

“One of the most important resources needed for this ecosystem to strive is you, the patient. We need to line-up our resources and keep the ecosystem going, including the patient community. There is no one better to bring together what others (physicians) can do than patients: you inspire all of us,” expressed Dolsten.

The Alpha-1 Foundation applauds and supports these types of initiatives, in which patients become partners and are of vital importance for therapeutic development. 

The panel also mentioned that it is critical to spread awareness and education in the medical community, and being able to have early diagnosis and detection, while mentioning the Accelerating Medicines Partnership (AMP), a public-private partnership between the NIH, the U.S. Food and Drug Administration (FDA), multiple biopharmaceutical, and life science companies, as well as non-profit organizations to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets for therapeutics.

The ultimate goal of AMP is to increase the number of new diagnostics and therapies for patients and reduce the time and cost of developing them.

“Patient participation is critical for AMP, especially to remind us what we are doing and why-and-who we are doing it for,” said Collins, who also mentioned the Foundation for the National Institutes of Health (FNIH) as being instrumental in bringing together funds and resources from both the private and public sectors, to work in mutual collaboration in research projects that will ultimately benefit the patient community.

The Alpha-1 Foundation applauds these types of initiatives that support research and bring innovative approaches to the table for the benefit of the patient community, as we are committed to finding a cure for Alpha-1 and improving the lives of Alphas, and those affected by the condition, worldwide.

For more information, please visit the Collaboration Ecosystem website and the AMP website.


Print

White House prepares to ban flavored e-cigs

Tuesday, September 17, 2019
The Trump administration said it is planning to ban all e-cigarette flavors following a recent nationwide outbreak of severe lung illnesses linked to vaping and five reported deaths, according to pool reports. President Donald Trump told...
Divider

Breaking a 10-year streak, the number of uninsured Americans rises

Friday, September 13, 2019
For the first time in a decade, the number of Americans without health insurance has risen — by about 2 million people in 2018 — according to the annual U.S. Census Bureau report. The Census found that 8.5% of the U.S. population...
Divider

House Speaker Nancy Pelosi to release drug pricing plan after Congress returns

Thursday, September 12, 2019
As published on the National Health Council Insider and other news outlets, House Speaker Nancy Pelosi will release a drug-pricing plan shortly after Congress returns to work after its August recess, a House Democratic aide confirmed. Democrats...
Divider

Study analyzes the degree of concordance among international guidelines regarding Alpha-1 Antitrypsin Deficiency

Thursday, September 12, 2019
The International Journal of Chronic Obstructive Pulmonary Disease recently published the outcomes of a study entitled “An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency,”...
Divider

The biological effects of double-dose alpha-1 antitrypsin augmentation therapy: A pilot clinical trial

Thursday, September 12, 2019
The American Journal of Respiratory and Critical Care Medicine, of the American Thoracic Society (ATS), recently published an article about the outcomes of a clinical trial entitled: “Effect of Double Dose of Alpha 1-antitrypsin Augmentation...
Divider

News and updates from the U.S. COPD Coalition

Wednesday, September 11, 2019
The U.S. COPD Coalition (USCC), which the Alpha-1 Foundation is a member of, has remained engaged in issues confronting our communities and continued its collaboration with other groups to positively impact access to diagnosis, treatment, and...
Divider

FDA and NIH public workshop: Agenda now available

Wednesday, September 4, 2019
The U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) are sponsoring the workshop entitled “Developing Therapeutics for Alpha-1 Antitrypsin Deficiency,” at the Natcher Conference Center, Building 45...
Divider

Update: CSL Behring announcement on their product Zemaira

Monday, August 19, 2019
The Alpha-1 Foundation received the following communication update from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1): "CSL Behring is...
Divider

DNA data shared in ways patients may find surprising

Tuesday, August 13, 2019
Deals between drugmakers and hospital systems to mine the genetic profiles of hospital patients are triggering concerns over the control of valuable genetic data. Drugmakers have been spending hundreds of millions of dollars for access to...
Divider

Arrowhead Pharmaceuticals doses first patient in SEQUOIA Phase 2/3 Study of ARO-AAT for treatment of Alpha-1 liver disease

Thursday, August 8, 2019
Arrowhead Pharmaceuticals Inc. announced that it has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference...
Divider

CSL Behring announcement on their product Zemaira

Tuesday, August 6, 2019
Today, the Alpha-1 Foundation received the following communication from CSL Behring, regarding Zemaira®, their prescription drug for augmentation therapy for the treatment of Alpha-1 Antitrypsin Deficiency (Alpha-1). “CSL Behring...
Divider

The 28th Annual Alpha-1 National Conference: The Alpha of Tomorrow

Tuesday, July 23, 2019
Orlando, Florida was the site of the largest gathering of Alphas, caregivers, family members, researchers, industry representatives, and the Alpha-1 community in the world, as the Alpha-1 Foundation held its 28th Annual Alpha-1 National...
Divider
12345678910Last

Article Search

Enter keywords in text box and click Search button for results.

Archive